Sontag Family Trust

Sontag Family Trust is a charitable organization dedicated to advancing brain cancer research. By supporting innovative projects and initiatives, the trust aims to enhance the understanding and treatment of this complex disease. It operates with a commitment to promoting scientific breakthroughs and improving patient outcomes, leveraging its resources to foster collaboration among researchers and healthcare professionals. The trust's focus on venture philanthropy further enables it to invest in promising ideas that can lead to significant advancements in brain cancer treatment and care. Through its efforts, the Sontag Family Trust seeks to make a meaningful impact on the fight against brain cancer.

Scott Davis

Senior Associate, Life Sciences

9 past transactions

Myosin Therapeutics

Seed Round in 2025
Myosin Therapeutics is a privately-held biopharmaceutical company dedicated to developing innovative medications for central nervous system (CNS) disorders and other significant unmet medical needs. The company focuses on creating novel drugs that target cellular motor proteins, which are essential molecular machines that convert energy into mechanical work within cells. This unique approach enables the potential treatment of various disease states, including cancer. By harnessing the capabilities of these motor proteins, Myosin Therapeutics aims to advance therapeutic options and improve patient outcomes in challenging medical areas.

TippingPoint Biosciences

Pre Seed Round in 2024
TippingPoint Biosciences is focused on developing therapeutics that address diseases linked to defects in DNA packaging, including various cancers and neurodegenerative disorders. Utilizing a drug discovery platform, the company aims to identify innovative treatments that specifically target unique genome packaging states associated with these diseases. This approach not only facilitates the treatment of cancers but also supports the development of stem cell therapies by addressing the underlying issues of dysfunctional genome packaging. Through its efforts, TippingPoint Biosciences seeks to advance medical care and improve patient outcomes in complex genetic conditions.

EnClear Therapies

Venture Round in 2024
EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

MimiVax

Venture Round in 2024
MimiVax, LLC is a clinical-stage biotechnology company based in Buffalo, New York, focused on developing immunotherapeutic vaccines and targeted therapies for cancer treatment. Founded in 2011, the company specializes in creating vaccines that utilize survivin-targeting technology, which aims to disrupt a cell-survival protein commonly found in various cancers. Its lead product, SurVaxM, is a peptide mimic immunotherapeutic vaccine designed to control tumor growth and recurrence, enhancing the potential for patient survival. Through its innovative approach, MimiVax seeks to provide healthcare providers with effective tools to improve cancer treatment outcomes.

Modifi Bio

Seed Round in 2023
Modifi Biosciences specializes in direct DNA modification and the creation of innovative cancer therapeutics. The company's primary focus is on altering tumor DNA in a way that makes cancer cells irreparable while preserving healthy cells. This distinctive methodology allows researchers to challenge and transform traditional approaches to oncology drug development. By exploiting DNA defects across various cancer types, Modifi Biosciences aims to provide effective treatments that target the underlying genetic issues in tumors, thereby advancing the field of cancer therapeutics.

Kiyatec

Venture Round in 2023
Kiyatec, LLC is a biotechnology company based in Greenville, South Carolina, specializing in the development of advanced 3D cell-based assays for preclinical drug discovery and clinical therapy applications. The company utilizes patients' own living tumor cells to create functional 3D models that facilitate testing of various cancer therapies, enhancing the predictive accuracy of drug responses. Its innovative 3DKUBE technology platform supports in situ imaging and accommodates different scaffold materials, allowing for the modeling of complex human biology through segregated cell co-culture. Kiyatec's services include drug response profiling, toxicity evaluation, and the development of cell-based models for testing small molecules, biologic drugs, and immunotherapies. The company also engages in contract research projects and collaborates with the National Cancer Institute to advance research on cancer types such as breast cancer, glioblastoma, and lung cancer. Founded in 2005, Kiyatec aims to assist medical practitioners in identifying effective treatments for cancer patients by providing insights prior to clinical trials.

AiM Medical Robotics

Venture Round in 2022
AiM Medical Robotics is focused on developing a robotic system specifically designed for neurosurgical procedures. This innovative system is MRI compatible, allowing patients to receive treatment while remaining in the MRI scanner. This capability enables physicians to obtain real-time imaging feedback, enhancing surgical precision and improving patient outcomes. The company's technology aims to assist in the treatment of various neurological conditions, including Parkinson's disease, epilepsy, tremors, and brain cancer. By integrating surgical planning with functional robotics, AiM Medical Robotics provides healthcare providers with the tools necessary for precise trajectory guidance in neurosurgery, ultimately enhancing the effectiveness of surgical interventions for functional brain disorders.

Agrivida

Series D in 2015
Agrivida, Inc. is an animal health and nutrition company that specializes in developing feed additives for various livestock, including poultry, swine, dairy, beef cattle, and aquaculture. Founded in 2003 and based in Four Seasons, Missouri, Agrivida focuses on innovative enzyme solutions to enhance animal nutrition. Its flagship product, GRAINZYME, utilizes advanced technology to produce beneficial enzymes such as phytase and glucanase within corn kernels. This approach allows for a natural and efficient means of integrating these enzymes into animal diets, promoting healthier livestock while also reducing environmental impact. Agrivida's mission is to provide effective nutrition solutions that support sustainable food production across the agriculture sector.

Alpheus Medical

Alpheus Medical specializes in developing innovative treatment solutions for solid body cancers, focusing primarily on aggressive brain tumors. The company has created a novel sonodynamic therapy platform that employs a non-invasive drug-device combination for the outpatient treatment of recurrent glioblastoma multiforme (rGBM). This approach utilizes photodynamic therapy, which involves using light delivered through a minimally invasive device to target cancer cells that have been exposed to a photosensitizer. By offering these advanced therapeutic options, Alpheus Medical aims to provide effective alternatives to traditional invasive brain surgeries, enhancing patient care and treatment outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.